ArticleJournal of thoracic disease2025
The hospital length of stay and mortality and its risk and protective factors among patients with acute respiratory distress syndrome receiving extracorporeal membrane oxygenation: a systematic review and meta-analysis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Value of the Lactate-to-Albumin and C-Reactive Protein-to-Albumin Ratios in COVID-19-Associated ARDS.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extracorporeal membrane oxygenation (ECMO) has emerged as an advanced therapeutic option for managing acute respiratory distress syndrome (ARDS), especially severe cases of ARDS. However, the mortality remains high among these patients. Therefore, this meta-analysis aims to evaluate the mortality rates and its potential risk and protective factors in ARDS patients receiving ECMO support. Methods: We systematically searched databases including PubMed, the Cochrane Library, Embase, and Web of Science for relevant studies from their respective inception to April 27, 2024. STATA 16 was used for data analysis. The quality of the included studies was assessed by the Newcastle-Ottawa Scale (NOS). Results: A total of 70 studies involving 31,666 ARDS patients were included. The overall mortality was 48% in ARDS patients receiving ECMO support, especially high in coronavirus disease 2019 (COVID-19) related ARDS patients (60%), and the average hospital length of stay (LOS) of survivors [standardized mean difference (SMD) =0.84, 95% CI: 0.30-1.38] was significantly longer than non-survivors. Moreover, the results showed that age [odds ratio (OR) =1.02, 95% confidence interval (CI): 1.01-1.03], body mass index (BMI) [hazard ratio (HR) =0.96, 95% CI: 0.9-0.98], Sequential Organ Failure Assessment (SOFA) score (OR =1.05, 95% CI: 1.02-1.08), ECMO driving pressure (OR =1.07, 95% CI: 1.05-1.10), immunocompromised status (OR =1.07, 95% CI: 1.05-1.09), and total respiratory rate from days 1 to 3 on ECMO (OR =1.04, 95% CI: 1.01-1.08) were all significant predictors for mortality. Conclusions: The current meta-analysis provides valuable insights into the intricate factors influencing mortality rate in ARDS patients on ECMO. The influencing factors for mortality should be further explored in the future, which may help reduce the global burden of ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.